0001493152-22-017665.txt : 20220624 0001493152-22-017665.hdr.sgml : 20220624 20220624081847 ACCESSION NUMBER: 0001493152-22-017665 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220622 FILED AS OF DATE: 20220624 DATE AS OF CHANGE: 20220624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Daugherty Frank Joseph CENTRAL INDEX KEY: 0001806875 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39555 FILM NUMBER: 221037015 MAIL ADDRESS: STREET 1: 2311 SPARTAN TRAIL CITY: SUGAR LAND STATE: TX ZIP: 77479 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Greenwich LifeSciences, Inc. CENTRAL INDEX KEY: 0001799788 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205473709 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3992 BLUEBONNET DR, BUILDING 14 CITY: STAFFORD STATE: TX ZIP: 77477 BUSINESS PHONE: 203-434-3290 MAIL ADDRESS: STREET 1: 3992 BLUEBONNET DR, BUILDING 14 CITY: STAFFORD STATE: TX ZIP: 77477 4 1 ownership.xml X0306 4 2022-06-22 0 0001799788 Greenwich LifeSciences, Inc. GLSI 0001806875 Daugherty Frank Joseph C/O GREENWICH LIFESCIENCES, INC. 3992 BLUEBONNET DR., BUILDING 14 STAFFORD TX 77477 1 1 0 0 Chief Medical Officer Stock Options 7.63 2022-06-22 4 A 0 104890 0 A 2032-06-22 Common Stock 104890 104890 D The options vest over time and pursuant to milestones. 2,185 of the options vest each month for 48 months contingent on the Company meeting certain performance milestones. The Reporting Person is eligible to exercise (i) 25% after the first site is activated for the Phase 3 clinical trial, (ii) 50% after completion of interim analysis of the Phase 3 clinical trial and (iii) 25% upon filing of Biologic License Application with the US Food and Drug Administration. /s/ Frank Daugherty 2022-06-24